PSC
PHVS icon

Piper Sandler & Co’s Pharvaris PHVS Stock Holding History

Piper Sandler & Co’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-181
Closed -$5.08K – 23
2023
Q4 		$5.08K Buy
+181
New +$3.66K ﹤0.01% 19

Other funds holding PHVS

GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Piper Sandler & Co's PHVS Position: Q1 2024 in Review

Piper Sandler & Co sold out of Pharvaris (PHVS) in Q1 2024, closing a stake of 181 shares — an estimated $5.08K sold.

Piper Sandler & Co first reported a position in PHVS in Q4 2023 and held it in 1 quarter. The position peaked at $5.08K in Q4 2023. 35 funds tracked by Wall St. Rank hold PHVS as of Q1 2024.

  • Piper Sandler & Co reported no remaining Pharvaris position as of Q1 2024 after selling out during the quarter.
  • Piper Sandler & Co sold 181 Pharvaris shares in Q1 2024, an estimated $5.08K.
  • Piper Sandler & Co first reported a position in Pharvaris in Q4 2023 and held it in 1 quarter.
  • Piper Sandler & Co's Pharvaris position peaked at $5.08K in Q4 2023.
  • 35 funds tracked by Wall St. Rank held Pharvaris as of Q1 2024.

Based on Piper Sandler & Co's 13F filing for Q1 2024, filed 13 May 2024.